Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-06-14
2009-10-27
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S192100, C514S002600, C514S012200, C530S350000, C536S023400
Reexamination Certificate
active
07608261
ABSTRACT:
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
REFERENCES:
patent: 6100071 (2000-08-01), Davis-Smyth et al.
patent: 6897294 (2005-05-01), Davis-Smyth et al.
patent: 2005/0281831 (2005-12-01), Davis-Smyth et al.
patent: 2006/0217311 (2006-09-01), Dix et al.
patent: WO 2005/000895 (2005-01-01), None
patent: WO 2006/047325 (2006-05-01), None
patent: WO 2006/104852 (2006-10-01), None
Dix Daniel
Frye Kelly
Furfine Eric
Graham Kenneth S.
Gregg, Esq. Valeta
Lockard Jon M
Regeneron Pharmacuticals, Inc.
Saoud Christine J
Smeland, Esq. Tor
LandOfFree
VEGF antagonist formulations suitable for intravitreal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with VEGF antagonist formulations suitable for intravitreal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VEGF antagonist formulations suitable for intravitreal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4094258